Novel proteomics test detects 95% of prostate cancers
Bethesda, MD-A screening technique based on the interplay of blood proteinsmay help clearly differentiate between prostate cancer and benign conditionslike BPH, according to a National Cancer Institute study. The test, whichis still under investigation, showed a specificity of 71% in men with marginallyelevated PSA levels, NCI researchers reported.
